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Abstract  
            Gene therapy has progressed from  a dream to a bedside reality in quite a few human 
diseases. From its first application in adenosine  deaminase deficiency, through the years,  its 
application has evolved to vascular angiogenesis and cardiac arrhythmias. Gene based biological 
pacemakers   using viral vectors or mesenchymal cells tested in animal models hold much 
promise. Induction of pacemaker activity within the left bundle branch can provide stable heart 
rates. Genetic modification of the AV node mimicking beta blockade can be therapeutic in the 
management of atrial fibrillation. G protein overexpression to modify the AV node also is 
experimental. Modification and expression of potassium channel genes altering the delayed 
rectifier potassium currents may permit better management of congenital long QT  syndromes. 
Arrhythmias in a failing heart are due to abnormal calcium cycling. Potential targets for genetic 
modulation include the sarcoplasmic reticulum calcium pump, calsequestrin and sodium calcium 
exchanger.Lastly the ethical concerns need to be addressed.
Key Words: Gene therapy; biological pacemakers; AV node modification; long QT syndromes; 
sarcoplasmic reticulum calcium pump
Introduction
               Gene therapy is defined as the transfer   of nucleic acids   to somatic cells as 
therapeutically useful molecules. Genetic defects can be corrected   or gene products   be 
expressed by gene therapy. This approach has many potential applications, the most obvious 
being the treatment of inherited monogenic disorders like cystic fibrosis. Human genome has 
approximately 30,000 genes. The genetic diversity is amplified by alternate splicing of mRNA 
and post translational modification of proteins. The possible gene targets  for arrhythmias is very 
large. Anti arrhythmic agents act by blocking the ion channels. These antiarrhythmics have poor 
channel specificity and may cross react with other ion channels. In addition they have poor 
affinity for the channels and have a narrow therapeutic window. The molecular targets of 
arrhythmia management are the ion channels and the modulators of ion channels like G proteins1.
Vectors for gene therapy
            A vector is the vehicle commonly used to introduce the gene to the target cell. Vectors 
may be RNA or DNA viruses or non viral in nature. Viruses which have the capacity to 
incorporate themselves in the host genome are used as vectors for gene therapy. The commonly 
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used viral vectors are genetically modified retroviruses, adenoviruses, adeno associated viruses 
and lentiviruses. These viral vectors are made replication deficient to ensure safety, but requires 
large amounts of vector particles for efficacy. Non viral vectors based on plasmids, DNA- lipid 
complexes   and   naked   DNA   are   also   used   since   they   lack   foreign   proteins   and   avoid 
immunological problems. None of the currently available vectors satisfy the criteria of an ideal 
gene therapeutic system. The feasibility of gene transfer has been demonstrated in both animals 
and humans.
               In contradistinction to the experimental laboratory, the extent of gene transfer and 
expression is   low in clinical settings. The period during which a newly introduced gene is 
expressed is variable and differs with the tissue, but is often short. For example, early-generation 
non-viral vectors express the gene at maximum levels only for a few days2. Many adenoviral 
vectors express the gene for 2-3 weeks3. Non viral vectors also have short duration of gene 
expression.   Short   duration   of   gene   expression   necessitates   repeat   dosing,   although   less 
efficacious. By contrast, expression from adeno-associated viral vectors may not peak for several 
weeks, but then remain constant in some tissues for several months4. Retroviruses produce a long 
lasting effect by integration of the transfected gene into the host genome5
Methods of gene delivery
               The classical methods of vector delivery are direct injection into the myocardium, 
infusion through the coronary arteries or administration to the epicardium.Various novel methods 
of transfection have been tried in animal models, including DNA polymer coating on inert 
materials and subsequent transfer to the atrial myocardium, with sustained gene activity6. 
Intracoronary perfusion is another modality of gene transduction with near  complete expression 
under optimal conditions7. The gene transfer efficiency depends on the coronary flow rate, virus 
concentration, virus exposure time and microvascular permeability. Agents which increase the 
microvascular permeability have been used to enhance the delivery. Each disease has its own 
target tissue and the amount of gene product required for treatment. So  only few generalizations 
can be made about the vector selection and the method of gene delivery.
The need for gene therapy in cardiac arrhythmias
            Antiarrhythmic medications suppress arrhythmias, but their systemic effects are often 
poorly tolerated and their proarrhythmic effects increase mortality. Radiofrequency ablation can 
cure   only   a   limited   number   of   arrhythmias.   Implantable   devices   can   be   curative   for 
bradyarrhythmias and lifesaving for tachyarrhythmias, but require a lifetime commitment to 
repeated procedures, have a significant expense, and may lead to severe complications. The need 
for new treatment strategies for cardiac arrhythmias has motivated the continuing development of 
gene therapeutic options  Gene therapy may prove to be a less intrusive, long-term solution to 
arrythmias than pacemakers or antiarrhythmic agents. Gene therapy for arrhythmias is a field still 
in its infancy.
            The ongoing research into gene therapy for  cardiac arrhythmias can be briefly discussed 
under:
1) Biological pacemakers
2) AV nodal modification
3) Long QT syndromes
4) Arrhythmias of cardiac failure
5) Ventricular arrhythmias
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 6(2): 111-118 (2006)Praveen S.V, Johnson Francis, Venugopal K, “Gene Therapy in Cardiac Arrhythmias”  113
Biological pacemakers
            Conventional electronic pacemakers although highly efficacious, have a finite battery life 
and problems related to lead and circuitry. Biological pacemakers aim a near physiological 
pacing by molecular or cellular targeting.Biological pacemakers can be cell therapy based or 
gene therapy based. Strategies have included gene therapy using naked plasmids or viral vectors 
and cell therapy  with both adult human mesenchymal stem cells (hMSCs) and human embryonic 
stem cells8,9. Over the past few  years, gene therapy has been used to explore the overexpression 
of   β2-adrenergic   receptors,   the   down-regulation   of   inward   rectifier   current,   and   the 
overexpression of pacemaker current as potential sources of biological pacemakers10. The protein 
product of HCN2 gene is a candidate for the pacemaker current. Rosen et al from Columbia 
university have recreated the biological pacemaker by  administering the pacemaker gene HCN2  
via viral vector or  in an hMSC platform to produce pacemaker function in the intact canine 
heart. Adenovirus containing the HCN2 gene [ad HCN2] on introduction in canine models  
produced  spontaneous  rhythms.
            Another potential approach to a biological pacemaker is the induction of pacemaker 
activity within the left bundle branch, thereby providing a ventricular escape rhythm with 
physiologically acceptable rates. The long-term stability and feasibility of this approach remain 
to be tested11. Adeno viral vectors have been tried in animal models to create pacemaker clones 
from ventricular myocytes. The inward rectifier current [IK1] is responsible for the maintenance 
of the resting membrane potential. The main subunit of this is Kir 2.1. The Kir 2.1 gene was  
mutated  to make it a dysfunctional channel (a dominant-negative), inserted into an adenoviral 
vector and  delivered to the hearts of guinea pigs. The enhanced automaticity of the ventricular 
myocytes   subsequent   to   the   gene   transfer   conferred   pacemaker   like   properties12.  
AV nodal modification
            As in case of biological pacemakers, the field is limited to animal studies. The major area 
of research in gene therapy for tachyarrhythmias now is on AV nodal modification to produce 
AV nodal block mimicking beta blockade.
            Genetic modification of AV node in an intracoronary perfusion model of porcine heart  
was reported by Donahue et al from John Hopkins University13. They infected porcine hearts 
with Adbetagal (recombinant adenovirus expressing Escherichia coli beta-galactosidase) or with 
AdGi [adenovirus encoding the Galphai2 subunit]. Galphai2 overexpression suppressed baseline 
atrioventricular conduction and slowed the heart rate during atrial fibrillation without producing 
complete heart block. In contrast, expression of the reporter gene beta-galactosidase had no 
electrophysiological effects. Reporter genes are nucleic acid sequences encoding easily assayed 
proteins.
            AV nodal gene transfer can decrease heart rates in animal models of atrial fibrillation. 
Inhibitory G protein overexpression  can prolong the AV nodal refractory period with slowing of 
conduction  resulting in reduced ventricular rates in atrial fibrillation14. In mouse models, cardiac 
overexpression of  adenosine receptor [A(3)AR] resulted in gene dose-dependent AV block and 
pronounced sinus nodal dysfunction in vivo. These may have future therapeutic implications for 
SA and AV nodal modification15. Focal gene transfer to the AV node  to produce a genetic 
calcium channel blocker  has been successful in experimental settings. Over expression of the 
ras  related small G- protein [Gem] in AV node slowed  AV nodal conduction  controlling the 
heart rate in atrial fibrillation16.
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Long QT syndromes ( LQTS)
            Sympathetic imbalance was  previously thought to be responsible for this disease. Since 
1991, 7 LQTS genes have been discovered and more than 300 mutations have been identified to 
account for the disease. Acquired LQTS, is presumed to be due to the blockade of the rapid 
component of the delayed rectifier K+ current (IKr). Blockage of the IKr prolongs the QT interval 
and increases the dispersion of repolarization, predisposing to torsades de pointes. Molecular 
genetic   analysis   could   be   useful   to   unravel   subclinical   mutations   or   polymorphisms.
               Individuals with cardiac potassium channel missense mutation, Q9E-hMiRP1 are 
predisposed to develop QT prolongation after clarithromycin administration. Experimental 
studies have demonstrated that cells transfected with plasmid DNA containing Q9E-hMiRP1 
have reduced potassium currents on exposure to clarithromycin.
            Site specific gene therapy for arrhythmias by transfecting cell clones with the K+ channel 
genes is a feasible approach to the management of LQTS17. Mutated K+ channels resulting in 
loss of function have been implicated in LQT 1 and 2. The potassium channel alpha subunit 
genes KCNH2 [HERG] and  KCNQ1 [KvLQT1] responsible for Ikr and Iks respectively are 
mutated in LQTS. In normal epithelia, KCNE3 [E3] interacts with the KVQT1 [Q1] thereby 
augmenting the potassium currents. E3 subunit can be genetically expressed in cardiac tissues 
[where it is normally scarce]   to abbreviate the action potential duration and enhance the 
potassium current.This potentially prevents arrhythmias in LQTS. Adenovirus encoded E3 
introduced into guinea pig ventricles shortened QT interval on homogenous transduction, but 
could be potentially arrhythmogenic if transduction is heterogenous18.
Arrhythmias of cardiac failure
               Abnormal calcium cycling plays an important role in the genesis of contractile 
dysfunction   and   arrhythmias   in   the   setting   of   heart   failure.   Genetic   modulation   of   the 
sarcoplasmic reticulum calcium ATP ase pump [SERCA] can have an ameliorating effect on the 
arrhythmias of cardiac failure. 
            Delayed repolarization predisposes the failing heart to  ventricular arrhythmias and this 
represents a logical target for gene therapy. The calcium ATPase SERCA1 was coexpressed with 
the potassium channel Kir2.1 in guinea pig hearts. Such myocytes  had bigger calcium transients 
and shorter action potentials. In vivo, repolarization was abbreviated, but contractile function 
remained unimpaired19. This shortening of repolarization prevents arrhythmias. Coexpression of 
SERCA1 prevented the decrease in contractility due to shortening of action potential. This 
interesting observation is useful in prevention of arrhythmias in the setting of heart failure.
               Calsequestrin, the high capacity calcium binding protein expressed in sarcoplasmic 
reticulum, also positively controls the rate of calcium release during excitation-contraction 
coupling. Mutations in the calsequestrin gene have been linked to arrhythmias and sudden death.  
For example, the recessive form of catecholaminergic polymorphic ventricular tachycardia is 
associated with calsequestrin mutations20. Modulation of the gene for calsequestrin could be one 
of the numerous potential targets for therapy.
            The main pathway for calcium efflux from the cell is the Na - Ca exchanger (NCX), a 
membrane antiporter  and a determinant of both the electrical and contractile state of the heart. 
NCX causes efflux of one Ca(2+) for three Na+ transported into the cell. Enhanced expression of 
NCX   has recently been recognised as one of the molecular mechanisms that contributes to 
reduced Ca(2+) release, impaired contractility and an increased risk of arrhythmias during the 
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development of cardiac hypertrophy and failure. The NCX also plays a crucial role in the 
pathogenesis of arrhythmias and cellular injury associated with ischaemia and reperfusion. 
Hence,   NCX   blockade   represents   a   potential   therapeutic   strategy   for   treating   cardiac 
disease.However, its reversibility and electrogenic properties must be taken into consideration 
when predicting the outcome. NCX inhibition has been demonstrated to be protective against 
ischaemic injury and to have a positive inotropic and antiarrhythmic effect in failing heart cells21.
            Failing hearts  show a delay of repolarization and  prolongation of action potential due to 
diminished  potassium  currents,  which is  proarrhythmic.  Adenovirus over- expressing  the 
potassium channels [AdShK] can reverse the prolongation of action potential duration, thereby 
potentially preventing arrhythmias22.
Ventricular arrhythmias 
               Electrical   alternans   has   been   linked   to   the   development   of   ventricular 
arrhythmias.Increasing the rapid component of the delayed rectifier current (IKr) may suppress 
electrical alternans and may be antiarrhythmic. IKr in isolated canine ventricular myocytes was 
increased by infection with an adenovirus containing the gene for the pore-forming domain of IKr 
[human ether-a-go-go gene (HERG)]. The voltage at which peak IKr occurred was significantly 
less negative in HERG-infected myocytes, thereby shifting the steady-state voltage-dependent 
activation and inactivation curves to less negative potentials23. This observation lend support to 
the idea that increasing IKr may be a viable approach to suppressing electrical alternans thereby 
suppressing arrhythmias.
Current problems with gene therapy
            As alluded to earlier, gene medicine is still in its infancy. Except for a  few  human trials, 
majority of trials to date have been in experimental animals.The expected result from gene 
therapy is a permanent cure of arrhythmias with a single stage treatment with minimal or no 
adverse effects. Obviously we are far from the ideal.    In the field of arrhythmias, an expectant  
waiting for the scenario to unfold in full is needed. The available vectors to date are far from 
ideal.Problems with vectors include variability in transfection capabilities,inefficient delivery at 
site,limited period of gene expression,   and immunogenicity. The tissue expression of many 
genes are transient. The level and efficiency of expression of many trans genes are suboptimal. 
Many viral vectors are potentially immunogenic and   carcinogenic. The interaction between 
vector and host genome can result in the vector being rendered replicant and lose  the therapeutic 
gene. Another area of concern is that the currently available vectors have less ability to transduce 
vascular cells than nonvascular cells. This could hamper efforts at cardiovascular gene transfer. 
Traditional vectors need to be engineered to increase their affinity for the target tissue or cell and 
prevent transduction to other cells24. 
            Succesful transfer of the therapeutic gene to all the myocytes at the target site is not fully 
achieved in the experimental settings. The receptors for many viral vectors are present in many 
tissues therby limiting the specificty of gene delivery.
            Many an arrhythmia with a diffuse substrate like atrial fibrillation needs the gene to be 
delivered to a wide area [the whole of the atrium]. The transfer methods like direct injection into 
myocardium fails to deliver the gene a short distance from the injecton site.    A special area of 
concern in arrhythmia gene therapy is the potential for the remedy itself being arrhythmogenic. 
Incomplete restoration may in also be arrhythmogenic. In a non linear system like biological 
organisms, making an isolated change in a specific aberration will result in restoration of normal 
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function only if the defect is truly isolated and is the direct cause of the phenotypic response.The 
long term response of a genetic modification in the myocardium is unknown at present. Only 
continued research and time can answer these problems with certainty.
The Future
               Newer refinements in vector development and design are needed to have better 
transduction in cardiovascular tissue. Cell specific regulatory elements and promoters to 
selectively target the cardiac tissue is a potential  area of interest25. Application at bed side awaits 
further refinement in gene delivery. Bactofection (bacterial gene delivery) as an alternative to 
viral vectors has been proposed26. Hybrid vectors, gutted vectors and new generation non viral 
vectors may hold the key to future research.  
Conclusion
            Given a wide plethora of potential targets for gene therapeutic strategies, the possible 
applications are unlimited. We have still a long way to go from animal models to the level of safe 
and efficacious application at the bedside. This awaits more refinements in gene delivery 
methods and vector designs. Not to be forgotten are the increasing concerns about safety. A 
regulated and sustained target tissue expression of the transduced gene with a wide index  of 
safety  should be the ultimate goal of any genetic intervention. 
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